REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009  Alemtuzumab (Campath 1H) is a monoclonal antibody that targets CD52, a cell surface molecule found on thymocytes, lymphocytes, monocytes and eosinophils. Early data suggested that the agent could reduce disability (Coles et al. J Neurol 2006; 253: 98-108), which led to the phase II CAMMS223 trial comparing alemtuzumab with beta-interferon-1a (CAMMS223 Investigators. N Engl J Med 2008; 359: 1786-1801).